OverviewSuggest Edit

Amoy Diagnostics (AmoyDx, 艾德生物) is a company that provides molecular diagnostic products and services for oncology precision medicine. It offers test kits, including NGS (next-generation sequencing), PCR (polymerase chain reaction), and FISH (fluorescence in situ hybridization) assays, as well as DNA and RNA extraction kits. The company serves healthcare providers, academic institutions, and pharmaceutical businesses.

TypePublic
Founded2008
HQXiamen, CN
Websiteamoydiagnostics.com

Latest Updates

Employees (est.) (Dec 2019)654(+21%)
Revenue (FY, 2019)¥578.4 M(+32%)
Share Price (Oct 2021)¥79
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amoy Diagnostics

Li-mou Zheng

Li-mou Zheng

Founder and CEO

Amoy Diagnostics Office Locations

Amoy Diagnostics has an office in Xiamen
Xiamen, CN (HQ)
39 Dingshan Road, Haicang District
Show all (1)

Amoy Diagnostics Financials and Metrics

Amoy Diagnostics Revenue

Embed Graph
View revenue for all periods
Amoy Diagnostics's revenue was reported to be ¥578.36 m in FY, 2019 which is a 31.7% increase from the previous period.
CNY

Revenue (H1, 2020)

283.0m

Gross profit (H1, 2020)

249.4m

Gross profit margin (H1, 2020), %

88.1%

Net income (H1, 2020)

80.8m

EBIT (H1, 2020)

93.3m

Market capitalization (15-Oct-2021)

17.5b

Closing stock price (15-Oct-2021)

79.0

Cash (30-Jun-2020)

362.4m

EV

17.2b
Amoy Diagnostics's current market capitalization is ¥17.5 b.
Annual
CNYFY, 2017FY, 2018FY, 2019

Revenue

330.4m439.0m578.4m

Revenue growth, %

33%32%

Cost of goods sold

25.2m39.4m55.7m

Gross profit

305.1m399.7m522.6m
Half Year
CNYH1, 2018H1, 2019H1, 2020

Revenue

202.5m265.9m283.0m

Cost of goods sold

16.3m25.0m33.6m

Gross profit

186.2m240.9m249.4m

Gross profit Margin, %

92%91%88%
Annual
CNYFY, 2017FY, 2018FY, 2019

Cash

167.8m198.2m498.4m

Accounts Receivable

141.0m188.9m233.1m

Prepaid Expenses

678.6k1.1m14.2m

Current Assets

509.4m564.9m797.4m
Half Year
CNYH1, 2018H1, 2019H1, 2020

Cash

193.9m252.9m362.4m

Accounts Receivable

165.8m213.3m265.0m

Prepaid Expenses

3.2m4.0m2.0m

Current Assets

570.4m705.8m947.9m
Annual
CNYFY, 2017FY, 2018FY, 2019

Net Income

94.1m126.7m135.5m

Depreciation and Amortization

16.4m19.7m24.2m

Inventories

(1.0m)(4.4m)(3.1m)

Accounts Payable

6.6m7.0m54.1m
Half Year
CNYH1, 2018H1, 2019H1, 2020

Net Income

69.6m78.2m80.8m

Depreciation and Amortization

9.4m11.8m13.1m

Inventories

(64.6k)(3.3m)(25.9m)

Accounts Payable

8.0m23.6m47.4m
CNYFY, 2017

Revenue/Employee

796.1k

Financial Leverage

1.1 x
Show all financial metrics

Amoy Diagnostics Operating Metrics

FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019H1, 2020

Medical Institutions Covered

300300400400500500

Medical Device Registration Certificates

181921222222

Patents (Domestic)

212429283234

Patents (Foreign)

333
Show all operating metrics

Amoy Diagnostics Acquisitions / Subsidiaries

Company NameDateDeal Size
Shanghai Shawei Biotechnology Co., Ltd.

Amoy Diagnostics Revenue Breakdown

Embed Graph

Amoy Diagnostics revenue breakdown by business segment: 13.9% from Testing Services, 82.7% from Pharmaceutical Manufacturing and 3.4% from Other

Amoy Diagnostics revenue breakdown by geographic segment: 11.3% from Foreign and 88.7% from Domestic

Show all human capital metrics

Amoy Diagnostics Online and Social Media Presence

Embed Graph

Amoy Diagnostics News and Updates

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib for China market. The CDx test is based on AmoyDx's industry-leading PCR platform. …

喜讯频传:艾德生物再获两项国家级认定

近日,工业和信息化部发布第二批专精特新“小巨人”企业名单,艾德生物被认定为第二批专精特新“小巨人”企业

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.

Amoy Diagnostics Frequently Asked Questions

  • When was Amoy Diagnostics founded?

    Amoy Diagnostics was founded in 2008.

  • Who are Amoy Diagnostics key executives?

    Amoy Diagnostics's key executives are Li-mou Zheng.

  • How many employees does Amoy Diagnostics have?

    Amoy Diagnostics has 654 employees.

  • What is Amoy Diagnostics revenue?

    Latest Amoy Diagnostics annual revenue is ¥578.4 m.

  • What is Amoy Diagnostics revenue per employee?

    Latest Amoy Diagnostics revenue per employee is ¥884.3 k.

  • Who are Amoy Diagnostics competitors?

    Competitors of Amoy Diagnostics include ZAI Lab, Thermo Fisher Scientific and Creative Biosciences.

  • Where is Amoy Diagnostics headquarters?

    Amoy Diagnostics headquarters is located at 39 Dingshan Road, Haicang District, Xiamen.

  • Where are Amoy Diagnostics offices?

    Amoy Diagnostics has an office in Xiamen.

  • How many offices does Amoy Diagnostics have?

    Amoy Diagnostics has 1 office.